YOU ARE HERE: Home > Guidelines and Clinical Policy > 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy ...

The Young Investigator Awards competition provides young scientific investigators with an opportunity to showcase their cutting-edge research. At ACC.27-WCC, 15 finalists will present their work in ...

This page features ACC's full coverage of the latest science from American Heart Association's (AHA) Scientific Sessions 2025, taking place Nov. 7–10 in New Orleans, LA.

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Young Scholars Alumni at ACC.24 in Atlanta. Young Scholars Describe Their Experience at ACC.22 in Washington, DC. The ACC Young Scholars Program is designed for high school students who are interested ...

In-hospital initiation of dapagliflozin in patients hospitalized for acute heart failure (HF) did not significantly reduce the short-term risk of worsening HF or death, based on findings from the DAPA ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

This page features ACC's full coverage of the latest science from American Heart Association's (AHA) Scientific Sessions 2023 – including trial summaries, news stories, journal scans, videos and more.

Digitoxin is beneficial in reducing the combined risk of heart failure (HF) hospitalization and all-cause mortality in patients with systolic HF. Maintaining serum digitoxin levels in a narrow ...

People with gender dysphoria taking hormone replacements as part of gender affirmation therapy face a substantially increased risk of serious cardiac events, including stroke, heart attack and ...